|1.||Jarius, S: 3 articles (01/2015 - 01/2015)|
|2.||Wildemann, B: 3 articles (01/2015 - 01/2015)|
|3.||Verbeek, Dineke S: 3 articles (03/2014 - 06/2005)|
|4.||Sakai, Norio: 3 articles (09/2011 - 09/2006)|
|5.||Seki, Takahiro: 3 articles (09/2011 - 09/2006)|
|6.||Saito, Naoaki: 3 articles (09/2011 - 11/2002)|
|7.||Sinke, Richard J: 3 articles (07/2008 - 06/2005)|
|8.||Klockgether, Thomas: 2 articles (08/2015 - 02/2014)|
|9.||Minnerop, Martina: 2 articles (08/2015 - 02/2014)|
|10.||Goedhart, Joachim: 2 articles (03/2014 - 07/2008)|
10/19/2001 - "This ipsilateral hyperalgesia induced by sciatic nerve ligation was significantly attenuated in protein kinase C gamma knockout mice. "
01/01/2013 - "The purpose of this study was to investigate the characterization of visceral nociception and hyperalgesia over time in rats exposed to PTSD-like stress, and to explore the potential role of protein kinase C gamma (PKCγ) in mediating visceral hyperalgesia following exposure to PTSD-like stress. "
08/06/2008 - "Protein kinase C gamma (PKCgamma), which is concentrated in interneurons of the inner part of lamina II of the dorsal horn, has been implicated in injury-induced allodynia, a condition wherein pain is produced by innocuous stimuli. "
10/19/2001 - "Reduced hyperalgesia induced by nerve injury, but not by inflammation in mice lacking protein kinase C gamma isoform."
07/21/2000 - "In control animals, PKC betaII immunoreactivity extended from lamina I into lamina III, while PKC gamma immunoreactivity was concentrated within laminae II and III. In ligated animals exhibiting thermal hyperalgesia, the content of both PKC betaII and gamma in the synaptosomal membrane fraction, but not crude cytosolic fraction, was significantly greater by an average of 40% from their respective controls. "
10/15/1994 - "Therapy with adoptively transferred PKC-gamma-transduced T cell clones and lines into syngeneic mice, with or without FBL-3 tumor, showed that the PKC-gamma-transduced T cells were not tumorigenic and were effective in curing mice with disseminated FBL-3."
12/01/1994 - "PKC gamma was expressed at a very low level in two of the colon tumors but could not be detected in the remaining tumors or any of the normal mucosa samples. "
07/30/2013 - "The main biological networks of HMs with cold and hot properties include cell cycle, cellular growth, proliferation and development, cancer, cytokine signaling, and intracellular and second messenger signaling; 11 specific pathways are presented to be perturbed only by HMs with the hot property, and the 27 specific target protein molecules include PRKACA, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKD1, TLR4, TLR7, TLR8, TLR9, HTR4, HTR6, HTR7, HTR2A, HTR1B, HTR2B, GNAO1, GNAI1, TNF, IL8, ROCK2, AKT1, MAPK1, RPS6KA1, RPS6KA3 and JAK2, which are involved in the biological network. "
12/01/1994 - "Fifteen minutes following topical treatment with a tumor promoting dose of TPA (3.4 nmol), the activities of PKC beta and PKC gamma decreased in the epidermal cytosol to 30% and 50% of control values, respectively, while these activities were increased in the epidermal particulate fraction by approximately 50%. "
01/01/1991 - "In this report, we show that transient expression of the PKC gamma isoenzyme can trans-activate a murine VL30 enhancer element in a pattern similar to that of the phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate. "
|3.||Spinocerebellar Ataxias (Spinocerebellar Ataxia)
12/01/2005 - "Spinocerebellar ataxia type 14: study of a family with an exon 5 mutation in the PRKCG gene."
06/01/2013 - "A novel mutation in the C2 domain of protein kinase C gamma associated with spinocerebellar ataxia type 14."
09/01/2006 - "Identification of a new family of spinocerebellar ataxia type 14 in the Japanese spinocerebellar ataxia population by the screening of PRKCG exon 4."
07/01/2006 - "Novel PRKCG/SCA14 mutation in a Dutch spinocerebellar ataxia family: expanding the phenotype."
02/01/2005 - "The protein kinase C gamma (PKCgamma) gene is mutated in spinocerebellar ataxia type 14 (SCA14). "
|4.||Osteosarcoma (Osteogenic Sarcoma)
07/01/2015 - "Further studies are needed to validate the coalition between PRKCG gene polymorphisms and risk of osteosarcoma relying on a larger population that included the participants in different ethnicity and hospital."
07/01/2015 - "The objective of the present study was to investigate the relationship between PRKCG polymorphisms and the risk of osteosarcoma. "
07/01/2015 - "Our results suggested that the T/C variant of rs454006 located in the intron 3 region of PRKCG gene was significantly associated with an increased risk of osteosarcoma (CC vs. TT, OR = 1.91; 95 % CI 1.29-2.85; P = 0.001; CC vs. TT+TC, OR = 2.14, 95 % CI = 1.48-3.09, P = 0.001; C vs. T, OR = 1.32, 95 % CI = 1.08-1.62, P = 0.008). "
07/01/2015 - "Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study."
12/01/2014 - "The rs454006 polymorphism of the PRKCG gene correlated to osteosarcoma susceptibility and might increase the risk of osteosarcoma. "
04/12/2005 - "In this large-scale study of PRKCG in patients with ataxia, two new missense mutations, an in-frame deletion, and a possible splice site mutation were found and can now be added to the four previously described missense mutations. "
08/01/2015 - "Autosomal dominant ataxia type 14 (SCA14) is a rare usually adult-onset progressive disorder with cerebellar neurodegeneration caused by mutations in protein kinase C gamma. "
10/01/2013 - "Our pathogenicity interpretation pathway predicted 13 different mutations in eight different genes: PRKCG, TTBK2, SETX, SPTBN2, SACS, MRE11, KCNC3 and DARS2 of which nine were novel including one causing a newly described recessive ataxia syndrome. "
06/01/2005 - "We subsequently screened the current Dutch ataxia cohort (approximately 900 individuals) for SCA14 mutations in the Cys2 region of the PRKCG gene. "
01/01/2005 - "To identify the disease-causing mutation in a large group of ataxia patients, we searched for mutations in the PRKCG gene. "
|1.||protein kinase C beta
|2.||protein kinase C gamma (PRKCG)
|4.||Complementary DNA (cDNA)
|6.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|7.||Microtubule-Associated Proteins (Microtubule-Associated Protein 2)
|8.||Carrier Proteins (Binding Protein)
|9.||Protein Kinase C-epsilon